Seer Inc - Class A

SEER | $1.67 -4.57% -4.79% 670K

(0.0% 1d) (-12.4% 1m) (-54.1% 1y) (0.0% 2d) (0.0% 3d) (-5.6% 7d) (-9.87% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 101,416,112
https://seer.bio
Sec Filling | Patents | 60 employees

Seek Inc. is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. The Company's Proteograph is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. The Company's designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers.

housing

add to watch list Paper trade email alert is off

Cyclo Therapeutics Inc - Class A

CYTH | $1.19 -0.83% -0.84% 57K

Professional, Scientific, and T...

(0.0% 1d) (-16.1% 1m) (69.2% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (-56.54% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 34,171,731
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Panbela Therapeutics Inc

PBLA | $0.4895 -6.31% 66K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (-96.3% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (49.66% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,376,454
http://www.sunbiopharma.com/
Sec Filling | Patents | 6 employees

(US) Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

cancer treatment pancreatic

add to watch list Paper trade email alert is off